Answers are grounded in this paper and cite their sources.
Background/Objectives: Clinical nodal classification may differ from postoperative pathological findings in lung cancer. We evaluated nodal discordance and mutation-specific outcomes in surgically treated, clinically node-positive epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. Methods: This retrospective study included patients with clinical N1–2, stage II–III disease treated at four Japanese institutions from 2012 to 2020. EGFR exon 19 deletion (Del19) and exon 21 L858R point mutation (L858R) were compared in exploratory postoperative and post-recurrence survival analyses. Results: Among 66 patients, 33 had Del19, 28 had L858R, and 5 had uncommon mutations; 52 underwent upfront surgery and 14 received preoperative treatment. Among 42 patients with clinical N1 disease, 18 (42.9%) had postoperative pathological N2 disease. The adjusted hazard ratio for postoperative overall survival with L858R versus Del19 was 1.99 (95% confidence interval, 0.97–4.09); the corresponding progression-free survival hazard ratio was 0.99 (0.54–1.81). In the pooled pathological common-mutation cohort, post-recurrence overall survival was evaluated in 33 patients with 25 deaths (univariable hazard ratio, 1.41; 95% confidence interval, 0.64–3.11; log-rank p = 0.388). Post-recurrence progression-free survival was evaluated in 26 patients and favored Del19 in an unadjusted comparison (log-rank p = 0.023). Conclusions: Nodal discordance was frequent in this selected surgical population. The imprecise survival estimates establish neither equivalent prognosis nor an independent adverse effect of L858R. Post-recurrence findings require external validation with treatment-adjusted analyses.
No takes yet. Share an insight, caveat, or question.
Manabe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: